HaiLi Biological: The price of the major asset purchase transaction has been adjusted to 536 million yuan.

Heilong Bio announced that the company has signed a supplementary agreement with Mellen Management Limited to adjust the price of a major asset purchase transaction. According to the evaluation by Beijing Zhuoxin Dahu Asset Appraisal Co., Ltd., the total equity value of Ruisheng Bio is 974 million yuan, a decrease from the original 1.7 billion yuan. Therefore, the transaction price has been adjusted from 935 million yuan to 536 million yuan, and Mellen Company will return the price difference of 399 million yuan. This adjustment does not affect the company's ownership of 55% equity in Ruisheng Bio, and it helps to reduce investment risks and risks of performance commitments not being met. The adjusted non-recurring net profit commitment for 2025 and 2026 are 50 million yuan and 58 million yuan, respectively.